Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
J Pediatr Hematol Oncol ; 44(1): e272-e274, 2022 01 01.
Article in English | MEDLINE | ID: mdl-33633025

ABSTRACT

Malignant peritoneal mesothelioma (MPM) is an extremely rare entity with a poor prognosis. We report on a 16-year-old boy with ascites and abdominal distension. A computed tomography scan showed peritoneal thickening and a mass adjacent to the transverse colon. Neither repeated cytologic testing of ascitic fluid, nor peritoneal tissue biopsy detected malignant cells. After the patient became progressively comatose, a magnetic resonance imaging scan of the brain showed leptomeningeal enhancement. An autopsy showed MPM infiltrating the pleura and the meninges. This is the first report on meningeal metastasis of MPM in a pediatric patient illustrating the enigmatic behavior of the tumor and highlighting the diagnostic pitfalls.


Subject(s)
Meningeal Neoplasms , Mesothelioma, Malignant , Peritoneal Neoplasms , Adolescent , Humans , Male , Meningeal Neoplasms/metabolism , Meningeal Neoplasms/pathology , Meningeal Neoplasms/secondary , Mesothelioma, Malignant/diagnosis , Mesothelioma, Malignant/pathology , Neoplasm Metastasis , Peritoneal Neoplasms/diagnosis , Peritoneal Neoplasms/pathology
2.
J Burn Care Res ; 43(2): 496-498, 2022 03 23.
Article in English | MEDLINE | ID: mdl-34695205

ABSTRACT

High-voltage burn injuries are rare in the pediatric age group, but can lead to devastating, severe sequelae. We present the cases of two young girls who suffered high-voltage burn injuries due to direct contact with overhead power lines. Both patients came from difficult psychosocial backgrounds. The injuries resulted in severe long-term consequences and functional deficits.


Subject(s)
Burns , Burns/etiology , Burns/therapy , Child , Female , Humans
5.
J Artif Organs ; 21(3): 367-370, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29404795

ABSTRACT

Most children with severe respiratory failure require extracorporeal membrane oxygenation (ECMO) for 7-10 days. However, some may need prolonged duration ECMO (> 14 days). To date, no consensus exists on how long to wait for native lung recovery. Here we report the case of a 3-year-old boy who developed severe necrotizing pneumonia requiring venovenous (VV) ECMO after 19 days of mechanical ventilation. In the first 4 weeks of his ECMO run, he showed no lung aeration, requiring total extracorporeal support. However, after we started strategies for promoting lung recovery such as daily prone positioning and regular use of toilet bronchoscopy and inhalative DNAse to clear secretions, by week five his tidal volumes gradually increased and he was successfully decannulated after 43 days. Moreover, we decided not to proceed to a surgical removal of the necrotic lung area. At present, he is 1-year post discharge and has fully recovered. This report shows that unexpected native lung recovery is possible even after prolonged loss of lung function and that a previous healthy lung can recover from apparent irreversible lung injury.


Subject(s)
Coinfection/therapy , Extracorporeal Membrane Oxygenation , Influenza, Human/therapy , Pneumonia, Necrotizing/therapy , Streptococcal Infections/therapy , Child, Preschool , Humans , Influenza A Virus, H1N1 Subtype , Influenza, Human/complications , Influenza, Human/physiopathology , Lung/microbiology , Lung/physiopathology , Male , Pneumonia, Necrotizing/complications , Pneumonia, Necrotizing/physiopathology , Streptococcal Infections/complications , Streptococcal Infections/physiopathology , Treatment Outcome
6.
Case Rep Cardiol ; 2013: 418565, 2013.
Article in English | MEDLINE | ID: mdl-24826287

ABSTRACT

A 14-year-old boy after balloon valvuloplasty of severe aortic valve stenosis in the neonatal period was referred for heart-lung transplantation because of high grade pulmonary hypertension and left heart dysfunction due to endocardial fibroelastosis with severe mitral insufficiency. After heart catheterization, hemodynamic parameters were invasively monitored: a course of levosimendan and initiation of diuretics led to a decrease of pulmonary capillary wedge pressure (from maximum 35 to 24 mmHg). Instead of an expected decrease, mean pulmonary artery pressures (mPAP) increased up to 80 mmHg with increasing transpulmonary pressure gradient (TPG) up to 55 mmHg. Oral bosentan and intravenous epoprostenol then led to a ~50% decrease of mPAP (TPG between 16 and 22 mmHg). The boy was listed solely for heart transplantation which was successfully accomplished 1 month later.

8.
Br J Haematol ; 148(1): 126-31, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19821829

ABSTRACT

In patients with leukaemia, acute respiratory distress syndrome (ARDS) secondary to intensified chemotherapy-induced immunosuppression is a devastating disorder resulting in high morbidity and mortality. Compared to standard indications for extracorporeal membrane oxygenation (ECMO), cytopenia further increases the risks of infection and bleeding. We describe the use of ECMO in four children with ARDS and leukaemia. Two patients (50%) survived, pulmonary function recovered and they are in prolonged first remission. The two other patients died from ARDS and pulmonary leukaemic infiltration. Although ECMO support is a high-risk setup for nosocomial infection we observed no additional septic episodes. All patients had a highly increased demand for packed platelet and red blood cell transfusions. This increased demand and unmanageable chronic bleeding into both lungs in one patient were probably caused by a combination of coagulopathy from the primary illness, the use of anticoagulants, chemotherapy-induced cytopenia, and a reduced survival rate of platelets and red cells due to permanent contact to foreign surface. We concluded that ECMO is a supportive tool to reduce the incidence of early death, treatment-related mortality and, ultimately, to improve overall survival in childhood leukaemia.


Subject(s)
Extracorporeal Membrane Oxygenation , Leukemia/complications , Respiratory Distress Syndrome/therapy , Adolescent , Female , Humans , Infant , Leukocyte Count , Male , Platelet Count , Respiratory Distress Syndrome/etiology
9.
Crit Care Med ; 38(2): 596-601, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19851091

ABSTRACT

OBJECTIVE: To study angiotensin-converting enzyme 2 in a piglet model with acute respiratory distress syndrome and to evaluate the therapeutic potential of this substance in a preclinical setting, as this model allows the assessment of the same parameters required for monitoring the disease in human intensive care medicine. The acute respiratory distress syndrome is the most severe form of acute lung injury with a high mortality rate. As yet, there is no specific therapy for improving the clinical outcome. Recently, angiotensin-converting enzyme 2, which inactivates angiotensin II, has been shown to ameliorate acute lung injury in mice. DESIGN: Prospective, randomized, double-blinded animal study. SETTING: Animal research laboratory. SUBJECTS: Fifteen anesthetized and mechanically ventilated piglets. INTERVENTIONS: Acute respiratory distress syndrome was induced by lipopolysaccharide infusion. Thereafter, six animals were assigned randomly into angiotensin-converting enzyme 2 group, whereas another six animals served as control. Three animals received angiotensin-converting enzyme 2 without lipopolysaccharide pretreatment. MEASUREMENTS AND MAIN RESULTS: Systemic and pulmonary hemodynamics, blood gas exchange parameters, tumor necrosis factor-alpha, and angiotensin II levels were examined before acute respiratory distress syndrome induction and at various time points after administering angiotensin-converting enzyme 2 or saline. In addition, ventilation-perfusion distribution of the lung tissue was assessed by the multiple inert gas elimination technique. Animals treated with angiotensin-converting enzyme 2 maintained significantly higher PaO2 than the control group, and pulmonary hypertension was less pronounced. Furthermore, angiotensin II and tumor necrosis factor-alpha levels, both of which were substantially increased, returned to basal values. Multiple inert gas elimination technique revealed a more homogeneous pulmonary blood flow after treatment with angiotensin-converting enzyme 2. In intergroup comparisons, there were no differences in pulmonary blood flow to lung units with subnormal ventilation/perfusion ratios. CONCLUSIONS: Angiotensin-converting enzyme 2 attenuates arterial hypoxemia, pulmonary hypertension, and redistribution of pulmonary blood flow in a piglet model of acute respiratory distress syndrome, and may be a promising substance for clinical use.


Subject(s)
Peptidyl-Dipeptidase A/therapeutic use , Pulmonary Circulation/drug effects , Respiratory Distress Syndrome/drug therapy , Acute Lung Injury/drug therapy , Angiotensin-Converting Enzyme 2 , Animals , Blood Gas Analysis , Disease Models, Animal , Female , Heart Rate/drug effects , Hypertension, Pulmonary/drug therapy , Lipopolysaccharides/pharmacology , Male , Peptidyl-Dipeptidase A/blood , Recombinant Proteins/therapeutic use , Swine , Tumor Necrosis Factor-alpha/blood , Ventilation-Perfusion Ratio/drug effects
10.
Neonatology ; 95(1): 86-90, 2009.
Article in English | MEDLINE | ID: mdl-18787342

ABSTRACT

BACKGROUND: Acute chylothorax in neonates is a rare disease but results in significant loss of lymphatic cells. OBJECTIVES: The purpose of the study was to determine whether acute chylothorax in neonates results in quantitative changes of lymphocyte subpopulations in peripheral blood and chyle. METHODS: 6 neonates who had acute chylothorax after thoracic surgery due to transposition of the great arteries were prospectively enrolled in the study. Peripheral blood mononuclear cells (PBMC) and chylous fluid mononuclear cells (CFMC) including CD45RA+ and CD45RO+ T cells and the expression of the lymphocyte homing marker CD62L were investigated by fluorescence-activated cell sorting. RESULTS: In chyle, CD3+CD45RA+ T cells were significantly increased compared to peripheral blood (PMBC: median 65.8% of CD3+; range 32.3-76.9% vs. CFMC: 90.3%; 68.6-94.4%) (p = 0.02). In chyle, changes of percentages of the CD45RA+ were limited to CD8-expressing T cells (CD8+CD45RA+: PBMC: 77.3%; 69.3-85.6% vs. CFMC: 93.2%; 86.3-98.5%) (p = 0.02). The CD8+CD45RA+ were mainly CD62L+ (PBMC: 59.4%; 31.6-62.0% vs. CFMC: 87.8%; 62.7-90.7%) (p = 0.02). CONCLUSIONS: The study gives evidence that acute chylothorax in neonates results in immunophenotypic alterations and accumulation of certain T-cell subpopulations in the pleural cavity. Although limited by small numbers of patients due to the rare manifestation of the disease, we were able to demonstrate an abundance of CD8+CD45RA+ T cells expressing CD62L in the chyle compared to peripheral blood. However, whether CD62L expression may contribute to the accumulation of CD8+CD45RA+ T cells in chyle and whether quantitative changes of these specific cells are of clinical relevance has to be determined.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Chylothorax/immunology , L-Selectin/analysis , Leukocyte Common Antigens/analysis , T-Lymphocyte Subsets/immunology , Acute Disease , Cell Separation , Chylothorax/blood , Flow Cytometry , Humans , Immunophenotyping , Infant, Newborn , Leukocyte Count , Leukocytes, Mononuclear/immunology , Monocytes/immunology , Prospective Studies
11.
High Alt Med Biol ; 9(3): 223-7, 2008.
Article in English | MEDLINE | ID: mdl-18800959

ABSTRACT

Excessive hypoxic pulmonary hypertension imposes right ventricular strain by increasing afterload that may lead to right heart failure and death. Increased phosphodiesterase activity, as well as increased levels of endothelin-1, has been discussed as molecular mechanisms. We investigated the hemodynamic and intrapulmonary effects of the intravenous dual endothelin A and B receptor blocker tezosentan, and of the phosphodiesterase-5 (PDE-5) antagonist vardenafil in a pig model of acute normobaric hypoxic pulmonary hypertension. Eighteen 4-week-old ventilated white farm pigs were exposed to normobaric hypoxia (FiO2 12%) and randomly assigned to three groups (n = 6) in order to receive either intravenous tezosentan or vardenafil or to serve as control. Arterial alveolar oxygen differences were the same with both drugs. After 90 min of treatment, pulmonary artery pressure and vascular resistance were significantly lower in both treatment groups when compared to controls (p < 0.001). Cardiac index increased significantly with vardenafil alone (2.8 l x min(-1) x m2 +/- 0.7 to 4.2 l x min x m2 +/- 0.7, p = 0.0003). Intravenous tezosentan, as well as vardenafil equipotently attenuate acute hypoxic pulmonary hypertension without afflicting pulmonary gas exchange. However, cardiac index increases with vardenafil only.


Subject(s)
Hypertension, Pulmonary/drug therapy , Hypoxia/drug therapy , Imidazoles/administration & dosage , Piperazines/administration & dosage , Pyridines/administration & dosage , Tetrazoles/administration & dosage , Vasodilator Agents/administration & dosage , Animals , Dose-Response Relationship, Drug , Female , Hemodynamics/drug effects , Injections, Intravenous , Male , Pulmonary Gas Exchange/drug effects , Random Allocation , Sulfones/administration & dosage , Swine , Triazines/administration & dosage , Vardenafil Dihydrochloride
12.
ASAIO J ; 54(5): 548-50, 2008.
Article in English | MEDLINE | ID: mdl-18812752

ABSTRACT

A 2-year-old boy was presented with late-recognized coarctation of the aorta and pulmonary hypertension due to left ventricular failure. The coarctation was corrected at the day of admission with a good postoperative result. However, weaning from the respirator failed despite multiple drug support due to left ventricular failure. Consequently, a left ventricular assist device (LVAD) was implanted 22 days later. The further course was complicated by systemic hypertension and ongoing pulmonary hypertension requiring extensive antihypertensive therapy. The first attempt to wean from LVAD failed and the left ventricle was left completely unloaded for additional 4 weeks. The second weaning attempt, using a very smooth weaning protocol, led to a recovered left ventricle and facilitated the removal of the assist device after a total of 120 days. The patient was discharged with normal cardiac function, but he still requires antihypertensive therapy. We believe that the slow reduction of the LVAD support was the key measure that leads to the successful weaning of the patient, thereby avoiding heart transplantation.


Subject(s)
Aortic Coarctation/surgery , Device Removal , Heart Failure/surgery , Heart-Assist Devices , Antihypertensive Agents/therapeutic use , Aorta/physiopathology , Aorta/surgery , Aortic Coarctation/diagnostic imaging , Carbazoles/therapeutic use , Carvedilol , Child, Preschool , Humans , Hydrochlorothiazide/therapeutic use , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/surgery , Length of Stay , Lisinopril/therapeutic use , Male , Propanolamines/therapeutic use , Treatment Outcome , Ultrasonography
13.
ASAIO J ; 54(5): 551-3, 2008.
Article in English | MEDLINE | ID: mdl-18812753

ABSTRACT

The use of venoarterial extracorporal membrane oxygenation and ventricular assist-devices in children with end stage heart failure is well established. The use of a bridge-to-bridge strategy leads to excellent survival rates in pediatric patients. We present an adolescent, who acquired acute respiratory failure, due to possible transfusion related lung injury, and who was successfully treated with venovenous extracorporal membrane oxygenation while on ventricular assist-device support.


Subject(s)
Extracorporeal Membrane Oxygenation , Heart Failure/therapy , Heart-Assist Devices , Respiratory Insufficiency/therapy , Acute Disease , Adolescent , Female , Follow-Up Studies , Heart Transplantation , Humans , Radiography , Respiratory Insufficiency/diagnostic imaging , Time Factors , Treatment Outcome
15.
Intensive Care Med ; 34(2): 368-76, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17898997

ABSTRACT

OBJECTIVE: Meconium aspiration induces acute lung injury (ALI) and subsequent pulmonary arterial hypertension (PAH) which may lead to right ventricular failure. Increase of endothelin-1, thromboxane-A, and phosphodiesterases are discussed molecular mechanisms. We investigated the intrapulmonary and hemodynamic effects of the intravenous dual endothelin A and B receptor blocker tezosentan and inhalational iloprost in a model of ALI due to meconium aspiration. DESIGN: Animal study. SETTING: University-affiliated research laboratory. SUBJECTS: White farm pigs. INTERVENTIONS: Acute lung injury was induced in 24 pigs by instillation of meconium. Animals were randomly assigned to four groups to receive either intravenous tezosentan, inhalational iloprost, or combined tezosentan and iloprost, or to serve as controls. MEASUREMENTS AND RESULTS: After meconium aspiration-induced lung injury each treatment increased oxyhemoglobin saturations (TEZO: 88 +/- 6% (p = 0.02), ILO: 85 +/- 13% (p = 0.05), TEZO-ILO: 89 +/- 6% (p = 0.02), control: 70 +/- 18%). TEZO but not ILO significantly decreased pulmonary arterial pressure and pulmonary vascular resistance (both p < 0.01). ILO alone decreased intrapulmonary shunt blood flow (p < 0.01). Compared with control, TEZO-ILO yielded the highest arterial partial pressure of oxygen (70 +/- 6 torr vs.49 +/- 9 torr, p = 0.04), although it decreased arterial blood pressure (change from 71 +/- 13 mmHg to 62 +/- 12 mmHg vs.85 +/- 14 mmHg to 80 +/- 11 mmHg (p = 0.01). CONCLUSIONS: Intravenous TEZO improves pulmonary gas exchange and hemodynamics in experimental acute lung injury secondary to meconium aspiration. Inhaled ILO improves gas exchange only, thereby reducing intrapulmonary shunt blood flow. Combination of TEZO and ILO marginally improves pulmonary gas exchange at the disadvantage of pulmonary selectivity.


Subject(s)
Meconium Aspiration Syndrome , Pyridines/pharmacology , Respiratory Distress Syndrome/drug therapy , Respiratory Distress Syndrome/etiology , Tetrazoles/pharmacology , Analysis of Variance , Animals , Hemodynamics/drug effects , Humans , Iloprost/pharmacology , Infant, Newborn , Injections, Intravenous , Pulmonary Gas Exchange/drug effects , Swine
16.
Pediatr Res ; 59(1): 147-50, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16327003

ABSTRACT

Acute pulmonary arterial hypertension in acute lung injury aggravates the clinical course and complicates treatment. Increased release and turnover of endogenous endothelin-1 is known to be a major determinant in the pathophysiology of pulmonary arterial hypertension of various etiologies. We tested whether intravenous tezosentan, a dual endothelin receptor antagonist, reduced pulmonary artery pressure in a pig model of acute lung injury induced by meconium aspiration. Acute pulmonary arterial hypertension was induced in 12 anesthetized and instrumented pigs by instillation of human pooled meconium in a 20% solution. Hemodynamic and gas exchange parameters were recorded every 30 min. Six animals received tezosentan 5 mg/kg after 0 and 90 min; six animals served as controls. Tezosentan led to a decrease of mean pulmonary artery pressure (PAP) from 33.4 +/- 4.0 mm Hg to 24.7 +/- 2.1 mm Hg and pulmonary vascular resistance (PVR) from 7.8 +/- 1.4 mm Hg.L(-1).min.m2 to 5.2 +/- 0.7 mm Hg.L(-1).min.m2. All animals treated with tezosentan survived, whereas in the control group four out of six animals died. Tezosentan improved survival and decreased pulmonary artery pressure in a porcine model of acute pulmonary arterial hypertension after meconium aspiration. Tezosentan has the potential for effective pharmacological treatment of pulmonary arterial hypertension following acute lung injury.


Subject(s)
Endothelin Receptor Antagonists , Hypertension, Pulmonary/drug therapy , Meconium Aspiration Syndrome/drug therapy , Pyridines/therapeutic use , Tetrazoles/therapeutic use , Animals , Blood Pressure/drug effects , Disease Models, Animal , Humans , Infant, Newborn , Pulmonary Artery/physiopathology , Pulmonary Gas Exchange , Pyridines/pharmacology , Survival Analysis , Sus scrofa , Tetrazoles/pharmacology , Vascular Resistance/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...